Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Batch Record in Pharmaceutical Industry in 2026: GMP Documentation, QA Review, and Batch Release Control

This article explains batch manufacturing record systems in the pharmaceutical industry, focusing on GMP documentation requirements, QA review processes, and pharmaceutical batch release process. It also highlights FDA GMP inspection findings, ALCOA+ data integrity, and CFR Part 11 compliance controls.
  • Blog, Quality Management System
Batch production record workflow in pharmaceutical manufacturing illustrating GMP documentation requirements, QA batch record review process, deviation control, and electronic batch record system aligned with CFR Part 11 electronic records and data integrity ALCOA plus compliance.

Sigma Healthcare Drops Boots Deal; Markets Rally on Strategy U-Turn

Sigma Healthcare pulled back from its early-stage attempt to acquire UK pharmacy giant Boots after concluding that the deal does not align with its strategic and capital priorities. The Australian pharmaceutical wholesaler shifted its focus back to its domestic market,
  • News
Sigma Healthcare Drops Boots Deal; Markets Rally on Strategy U-Turn

Talvey’s Phase 3 Breakthrough Reshapes Myeloma Care; Progression Risk Falls 72%

Johnson & Johnson unveiled phase 3 findings at the European Hematology Association Congress 2026 in Stockholm, highlighting the growing impact of bispecific antibodies in multiple myeloma treatment. Results from the MonumenTAL-3 phase 3 study showed that Talvey combined with Darzalex
  • News
Talvey’s Phase 3 Breakthrough Reshapes Myeloma Care; Progression Risk Falls 72%

Batch Management in Pharmaceutical Industry in 2026: GMP Failures, Data Integrity, and Inspection Risks

Explore critical aspects of pharmaceutical batch control, focusing on documentation accuracy, electronic batch records, ALCOA plus principles, and GMP compliance. This article explains inspection risks, quality unit review, and batch release process for improved inspection readiness.
  • Blog, Computerized System Validation
Pharmaceutical production workflow showing electronic batch records, data integrity pharmaceutical manufacturing, ALCOA plus principles, and traceability controls for GMP inspection readiness.

Lilly Ajax Data Shock; JAK2 Breakthrough Works Right Out of Gate

Eli Lilly has unveiled early clinical results from its Ajax Therapeutics acquisition at the European Hematology Association (EHA) 2026 meeting, showing strong activity of a next-generation JAK2 inhibitor in patients with myelofibrosis who had already failed prior therapies. The data
  • News
Lilly Ajax Data Shock; JAK2 Breakthrough Works Right Out of Gate

FDA Expands Tzield for Children; But Keeps Deadly Infection Warning

The U.S. Food and Drug Administration has expanded the indication of Tzield, developed by Sanofi SA, to include children and adolescents aged 8 to 17 who have recently been diagnosed with stage 3 type 1 diabetes. This update broadens the
  • News
FDA Expands Tzield for Children; But Keeps Deadly Infection Warning

FDA Moves to Pull Tavneos; Liver Safety Signals Trigger EMA and Global Review

Tensions between Amgen and the U.S. Food and Drug Administration have intensified after the regulator raised serious safety concerns regarding Amgen and pushed for its voluntary withdrawal from the market. The FDA pointed to emerging safety signals and post-marketing adverse
  • News
FDA Moves to Pull Tavneos; Liver Safety Signals Trigger EMA and Global Review

Sanofi CIDP Trial Collapses; What Phase 3 Revealed That Phase 2 Missed

Sanofi has discontinued its Phase 3 MOBILIZE study of Sanofi riliprubart in chronic inflammatory demyelinating polyneuropathy after an interim analysis showed the trial was unlikely to demonstrate sufficient efficacy, according to a June 10, 2026 update. The decision followed an
  • News
Sanofi CIDP Trial Collapses; What Phase 3 Revealed That Phase 2 Missed